CN108310392A - A kind of preparation method of medical graphene oxide antiseptic - Google Patents
A kind of preparation method of medical graphene oxide antiseptic Download PDFInfo
- Publication number
- CN108310392A CN108310392A CN201810103737.4A CN201810103737A CN108310392A CN 108310392 A CN108310392 A CN 108310392A CN 201810103737 A CN201810103737 A CN 201810103737A CN 108310392 A CN108310392 A CN 108310392A
- Authority
- CN
- China
- Prior art keywords
- graphene oxide
- added
- medical
- solution
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Carbon And Carbon Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of preparation methods of medical graphene oxide antiseptic, including：Carboxyethylsilane triol sodium-salt aqueous solution is taken to be added in 2 morpholino b acid buffer solutions；1 (3 dimethylamino-propyl) 3 ethyl carbodiimides and 1 (3 dimethylamino-propyl) 3 ethyl carbodiimides are added into solution；Tetrapeptide is added in above-mentioned solution, is reacted；Card is received into mycin and is dissolved in 2 morpholino b acid buffer solutions, reaction solution is then added, the reaction was continued；Graphene oxide dispersion is prepared, is mixed with reaction solution, after being reacted under the conditions of 50 80 DEG C, dialysis is carried out 7 10 days and freeze-drying, obtains medical graphene oxide antiseptic.Preparation method is simple by the present invention, reaction condition is mild, it is environmentally protective and efficient, prepared medical graphene oxide antiseptic, not only there is good biocompatibility, but also 100% can be reached to Escherichia coli bacteriostasis rate, fungistatic effect is notable, kanamycins will not be discharged when in use, and it is indiscriminate to effectively prevent antibiotic.
Description
Technical field
The present invention relates to bio-medical anti-biotic material field, more particularly to a kind of preparation of medical graphene oxide antiseptic
Method.
Background technology
As the improvement of people's living standards, people are constantly enhancing the consciousness of health.But it is various pathogenic
Microorganism is very extensive in distributed in nature, their growth and breeding seriously threaten the health of the mankind.Thus, safety is high
The research and development of the antiseptic of effect and low cost has been to be concerned by more and more people.Existing most of antiseptics belong to release
Type is usually supported in the carrier, its antibacterial action is played by constantly discharging into bacterial body.This can lead to antibacterial
Performance constantly reduces, until disappear, therefore the non-release type antiseptic of exploitation seems particularly significant.Non-release type antiseptic does not need
By discharging drug, it is only necessary to be killed bacterium by achieving the purpose that with being in direct contact for bacterium.Meeting antibacterial demand
While extend usage time as possible；The problem of can additionally being remained to avoid drug toxicity.Therefore, change the antibiotic property of antiseptic
Can persistently it stablize, it is less toxic or nontoxic, the safety and health of the mankind are significantly improved.
Graphene oxide is a kind of Graphene derivative, and abundant oxygen-containing group is connected on its basal plane, is contained in plane
Hydroxyl and epoxy group, edge contain carboxyl, these functional groups impart the certain chemism of graphene oxide, make it easier to repair
Decorations.It is found by numerous studies, the anti-microbial property unobvious of graphene oxide.Therefore, using small peptide and antibiotic to aoxidizing stone
Black alkene is modified, its performance is made to significantly improve, such as is reduced its toxicity, improved bioactivity, avoid abuse of antibiotics.Together
When, the required less investment of this research and development, and preparation method is simple, green non-pollution, has in bio-medical anti-biotic material higher
Application value.
Invention content
Goal of the invention：To solve the above-mentioned problems, the present invention provides a kind of preparation side of medical graphene oxide antiseptic
Method, this method is simple and practicable, and reaction condition is mild, environmentally protective and efficient, has in bio-medical anti-biotic material field higher
Application value.
Technical solution：In order to achieve the above-mentioned object of the invention, the technical solution adopted by the present invention is as follows：
A kind of preparation method of medical graphene oxide antiseptic, includes the following steps：
1) it takes the aqueous solution of three sodium alkoxide of carboxyethylsilane to be added in 2-morpholine ethane sulfonic acid buffer solution, makes carboxy ethyl
Between silantriol sodium salt concentration range 1-8%, stir 10-30 minutes；
2) 1- (3- dimethylamino-propyls) -3- ethyl carbodiimides and 1- (3- diformazan ammonia are added into the solution of step 1)
Base propyl) -3- ethyl carbodiimides, a concentration of 1-4mM, 1- (3- bis- of 1- (3- dimethylamino-propyls) -3- ethyl carbodiimides
Methylaminopropyl) -3- ethyl carbodiimides a concentration of 4-10mM, stir 30-120 minutes；
3) tetrapeptide is added in above-mentioned solution, makes its concentration range between 0.05-0.6mg/mL, reacted 1-4 hours；
4) card is received into mycin and is dissolved in 2-morpholine ethane sulfonic acid buffer solution, make its concentration range 0.05-0.6mg/mL it
Between；
5) reaction solution of step 3) is added in above-mentioned solution, reacts 2-6 hours；
6) graphene oxide dispersion is added in absolute ethyl alcohol, is ultrasonically treated, obtains a concentration of 0.25-1.5mg/mL's
Graphene oxide dispersion；
7) step 5) reaction solution is mixed with graphene oxide dispersion, is stirred 12-24 hours under the conditions of 50-80 DEG C,
Dialysis 7-10 days, freeze-drying, obtains medical graphene oxide antiseptic.
In step 1), the pH ranges of the 2-morpholine ethane sulfonic acid buffer solution are between 5.5-6.5.
In step 1), a concentration of the 25% of the water concentration of three sodium alkoxide of carboxyethylsilane.
In step 3), the tetrapeptide is arginine-glycine-aspartic acid-lysine (commercially available).
The kanamycins is kanamycin sulfate.
In step 6), the supersound process is that ultrasound 300-1000W is handled 5-30 minutes.
The obtained medical graphene oxide antiseptic of preparation method of the medical graphene oxide antiseptic.
The medical graphene oxide antiseptic, structural formula are as follows：
Application of the medical graphene oxide antiseptic in antibacterial.
Advantageous effect：Compared with prior art, the preparation method of medical graphene oxide antiseptic of the invention, solvent are
2-morpholine ethane sulfonic acid buffer solution need not be protected from light, and be a kind of green, environmentally friendly, convenient and efficient preparation method.This method can
Kanamycins and tetrapeptide to be grafted on graphene oxide, effectively kanamycins, tetrapeptide and graphene oxide are closed
The use in conjunction of reason.Prepared medical graphene oxide antiseptic not only has good biocompatibility, but also to large intestine
Bacillus bacteriostasis rate can reach 100%, and fungistatic effect is notable, in the case of same bacteriostasis rate, effectively reduce card and receive mycin
Dosage.In use, medical graphene oxide antiseptic will not discharge kanamycins, effectively prevent abuse of antibiotics and cause
Drug resistance and superbacteria generate the problems such as, have good practicability.
Description of the drawings
Fig. 1 is the atomic force microscopy diagram of medical graphene oxide antiseptic；
Fig. 2 is the transmission electron microscope picture of medical graphene oxide antiseptic；
Fig. 3 is inhibition zone picture of the medical graphene oxide antiseptic to Escherichia coli.
Specific implementation mode
With reference to specific embodiment, the present invention is described further.
Embodiment 1
A kind of preparation method of medical graphene oxide antiseptic, steps are as follows：
1) take the aqueous solution of three sodium alkoxide 25% of carboxyethylsilane that 2-morpholine ethane sulfonic acid buffer solution (pH=5.5) is added
In, make three sodium alkoxide of carboxyethylsilane a concentration of 2%, stirs 10 minutes；
2) 1- (3- dimethylamino-propyls) -3- ethyl carbodiimides and 1- (3- dimethylaminos third are added into 1) solution
Base) -3- ethyl carbodiimides, it is respectively 1.5mM and 5mM to make its concentration, is stirred 60 minutes；
3) tetrapeptide is added in above-mentioned solution, makes its a concentration of 0.2mg/mL, reacted 1 hour；
4) card is received into mycin and is dissolved in 2-morpholine ethane sulfonic acid buffer solution, make its a concentration of 0.2mg/mL；
5) it is added in the reaction solution of step 3), reacts 4 hours in above-mentioned solution；
6) graphene oxide dispersion is added in absolute ethyl alcohol, ultrasonic 1000W is handled 5 minutes, is obtained a concentration of
The graphene oxide dispersion of 0.5mg/mL；
7) step 5) reaction solution is mixed with graphene oxide dispersion, is stirred 12 hours under the conditions of 70 DEG C, dialysis 7
It, freeze-drying obtains medical graphene oxide antiseptic.The structural formula of the medical graphene oxide antiseptic obtained, such as
Shown in lower：
The medical graphene oxide antiseptic of preparation is tested for the property, it is specific as follows：
1) atomic force microscope is tested
The atomic force microscopy diagram of medical graphene oxide antiseptic, as shown in Figure 1.The thickness of single-layer graphene oxide is
1 ran, and as can be seen from the figure the thickness of medical graphene oxide antiseptic is obviously thickened, and increases to 3.5 nanometers.
2) transmissioning electric mirror test
The transmission electron microscope photo of medical graphene oxide antiseptic, as shown in Figure 2.Single-layer graphene oxide is translucent
Laminated structure, and as can be seen from Figure 2 the translucence of medical graphene oxide antiseptic is substantially reduced, and is switched to opaque
Sheet, it is consistent with atomic force microscope result, show the successful preparation of medical graphene oxide antiseptic.
3) inhibition zone is tested
By medical graphene oxide antiseptic dispersant liquid drop on circular filter paper, it is dried and ultraviolet-sterilization processing.It will
Bacterium solution containing a certain amount of Escherichia coli is uniformly applied on solid medium, then sterile sample is placed on culture medium,
It is incubated overnight for 37 DEG C in constant incubator.
Medical graphene oxide antiseptic is to the inhibition zone photos of Escherichia coli, as shown in Figure 3.It can be clearly from figure
See inhibition zone do not occur around medical graphene oxide antiseptic, illustrates medical graphene oxide prepared by this method
The problems such as antiseptic will not discharge kanamycins, and drug resistance caused by effectively preventing abuse of antibiotics and superbacteria generate.
Embodiment 2
A kind of preparation method of medical graphene oxide antiseptic, steps are as follows：
1) take the aqueous solution of three sodium alkoxide 25% of carboxyethylsilane that 2-morpholine ethane sulfonic acid buffer solution (pH=6.5) is added
In, make three sodium alkoxide of carboxyethylsilane a concentration of 6%, stirs 20 minutes；
2) 1- (3- dimethylamino-propyls) -3- ethyl carbodiimides and 1- (3- dimethylaminos third are added into 1) solution
Base) -3- ethyl carbodiimides, it is respectively 4mM and 8mM to make its concentration, is stirred 100 minutes；
3) tetrapeptide is added in above-mentioned solution, makes its a concentration of 0.3mg/mL, reacted 3 hours；
4) card is received into mycin and is dissolved in 2-morpholine ethane sulfonic acid buffer solution, make its a concentration of 0.3mg/mL；
5) it is added in the reaction solution of step 3), reacts 2 hours in above-mentioned solution；
6) graphene oxide dispersion is added in absolute ethyl alcohol, ultrasonic 600W is handled 15 minutes, obtains a concentration of 1mg/
The graphene oxide dispersion of mL；
7) step 5) reaction solution is mixed with graphene oxide dispersion, is stirred 24 hours under the conditions of 60 DEG C, dialysis 10
It, freeze-drying obtains medical graphene oxide antiseptic.
Embodiment 3
A kind of preparation method of medical graphene oxide antiseptic, steps are as follows：
1) take the aqueous solution of three sodium alkoxide 25% of carboxyethylsilane that 2-morpholine ethane sulfonic acid buffer solution (pH=6) is added
In, make three sodium alkoxide of carboxyethylsilane a concentration of 10%, stirs 15 minutes；
2) 1- (3- dimethylamino-propyls) -3- ethyl carbodiimides and 1- (3- dimethylaminos third are added into 1) solution
Base) -3- ethyl carbodiimides, it is respectively 3mM and 10mM to make its concentration, is stirred 40 minutes；
3) tetrapeptide is added in above-mentioned solution, makes its a concentration of 0.25mg/mL, reacted 4 hours；
4) card is received into mycin and is dissolved in 2-morpholine ethane sulfonic acid buffer solution, make its a concentration of 0.25mg/mL；
5) it is added in the reaction solution of step 3), reacts 2 hours in above-mentioned solution；
6) graphene oxide dispersion is added in absolute ethyl alcohol, ultrasonic 500W is handled 15 minutes, is obtained a concentration of
The graphene oxide dispersion of 0.75mg/mL；
7) step 5) reaction solution is mixed with graphene oxide dispersion, is stirred 18 hours under the conditions of 80 DEG C, dialysis 10
It, freeze-drying obtains medical graphene oxide antiseptic.
Embodiment 4
A kind of preparation method of medical graphene oxide antiseptic, steps are as follows：
1) take the aqueous solution of three sodium alkoxide 25% of carboxyethylsilane that 2-morpholine ethane sulfonic acid buffer solution (pH=5.5) is added
In, make three sodium alkoxide of carboxyethylsilane a concentration of 5%, stirs 20 minutes；
2) 1- (3- dimethylamino-propyls) -3- ethyl carbodiimides and 1- (3- dimethylaminos third are added into 1) solution
Base) -3- ethyl carbodiimides, it is respectively 5mM and 9mM to make its concentration, is stirred 50 minutes；
3) tetrapeptide is added in above-mentioned solution, makes its a concentration of 0.35mg/mL, reacted 4 hours；
4) card is received into mycin and is dissolved in 2-morpholine ethane sulfonic acid buffer solution, make its a concentration of 0.35mg/mL；
5) it is added in the reaction solution of step 3), reacts 4 hours in above-mentioned solution；
6) graphene oxide dispersion is added in absolute ethyl alcohol, ultrasonic 300W is handled 20 minutes, is obtained a concentration of
The graphene oxide dispersion of 1.2mg/mL；
7) step 5) reaction solution is mixed with graphene oxide dispersion, is stirred 20 hours under the conditions of 75 DEG C, dialysis 8
It, freeze-drying obtains medical graphene oxide antiseptic.
Embodiment 5
A kind of preparation method of medical graphene oxide antiseptic, steps are as follows：
1) take the aqueous solution of three sodium alkoxide 25% of carboxyethylsilane that 2-morpholine ethane sulfonic acid buffer solution (pH=6.2) is added
In, make three sodium alkoxide of carboxyethylsilane a concentration of 5%, stirs 30 minutes；
2) 1- (3- dimethylamino-propyls) -3- ethyl carbodiimides and 1- (3- dimethylaminos third are added into 1) solution
Base) -3- ethyl carbodiimides, it is respectively 2.5mM and 6mM to make its concentration, is stirred 80 minutes；
3) tetrapeptide is added in above-mentioned solution, makes its a concentration of 0.5mg/mL, reacted 3.5 hours；
4) card is received into mycin and is dissolved in 2-morpholine ethane sulfonic acid buffer solution, make its a concentration of 0.5mg/mL；
5) it is added in the reaction solution of step 3), reacts 3.5 hours in above-mentioned solution；
6) graphene oxide dispersion is added in absolute ethyl alcohol, ultrasonic 400W is handled 30 minutes, is obtained a concentration of
The graphene oxide dispersion of 1.5mg/mL；
7) step 5) reaction solution is mixed with graphene oxide dispersion, is stirred 16 hours under the conditions of 65 DEG C, dialysis 7
It, freeze-drying obtains medical graphene oxide antiseptic.
Embodiment 6
A kind of preparation method of medical graphene oxide antiseptic, steps are as follows：
1) take the aqueous solution of three sodium alkoxide 25% of carboxyethylsilane that 2-morpholine ethane sulfonic acid buffer solution (pH=5.8) is added
In, make three sodium alkoxide of carboxyethylsilane a concentration of 8%, stirs 25 minutes；
2) 1- (3- dimethylamino-propyls) -3- ethyl carbodiimides and 1- (3- dimethylaminos third are added into 1) solution
Base) -3- ethyl carbodiimides, it is respectively 4.5mM and 9mM to make its concentration, is stirred 120 minutes；
3) tetrapeptide is added in above-mentioned solution, makes its a concentration of 0.45mg/mL, reacted 3.5 hours；
4) card is received into mycin and is dissolved in 2-morpholine ethane sulfonic acid buffer solution, make its a concentration of 0.45mg/mL；
5) it is added in the reaction solution of step 3), reacts 3.5 hours in above-mentioned solution；
6) graphene oxide dispersion is added in absolute ethyl alcohol, ultrasonic 700W is handled 25 minutes, is obtained a concentration of
1.25mg/mL graphene oxide dispersion；
7) step 5) reaction solution is mixed with graphene oxide dispersion, is stirred 14 hours under the conditions of 70 DEG C, dialysis 10
It, freeze-drying obtains medical graphene oxide antiseptic.
7 bacteriostasis property of embodiment is tested
Using liquid cultivating system, the Escherichia coli cultivated in advance are added in 10mL pancreas peptone soybean broth culture mediums
Bacterium solution, make its a concentration of 1 × 108CFU/mL is separately added into the medical graphene oxides of 10mg to be not added with sample as blank control group
Antiseptic, 10mg graphene oxides, 10mg cards receive mycin, 10mg tetrapeptides, and after being cultivated 5 hours in 37 DEG C of shaking table, use is dilute
The method for applying tablet is released, surviving bacteria is counted, bacteriostasis rate is calculated by following equation：
R (%)=(NBlank-NSample)/NSample× 100%
Wherein, NBlankAnd NSampleRespectively in blank control conical flask and the medical graphene oxide antiseptic conical flask of addition
Clump count.By calculating, the results are shown in Table 1 for bacteriostasis rate.
Table 1 is the bacteriostasis rate of prepared medical graphene oxide antiseptic
By table 1 it is known that the medical graphene oxide antiseptic prepared in embodiment is equal to the bacteriostasis rate of Escherichia coli
100% can be reached.In the case of same bacteriostasis rate, effectively reduces card and receive the dosage of mycin.
Claims (9)
1. a kind of preparation method of medical graphene oxide antiseptic, which is characterized in that include the following steps：
1) it takes the aqueous solution of three sodium alkoxide of carboxyethylsilane to be added in 2-morpholine ethane sulfonic acid buffer solution, makes carboxyethylsilane
Between three sodium alkoxide concentration range 1-8%, stir 10-30 minutes；
2) 1- (3- dimethylamino-propyls) -3- ethyl carbodiimides and 1- (3- dimethylaminos third are added into the solution of step 1)
Base) -3- ethyl carbodiimides, a concentration of 1-4mM of 1- (3- dimethylamino-propyls) -3- ethyl carbodiimides, 1- (3- diformazan ammonia
Base propyl) -3- ethyl carbodiimides a concentration of 4-10mM, stir 30-120 minutes；
3) tetrapeptide is added in above-mentioned solution, makes its concentration range between 0.05-0.6mg/mL, reacted 1-4 hours；
4) card is received into mycin and is dissolved in 2-morpholine ethane sulfonic acid buffer solution, make its concentration range between 0.05-0.6mg/mL；
5) reaction solution of step 3) is added in above-mentioned solution, reacts 2-6 hours；
6) graphene oxide dispersion is added in absolute ethyl alcohol, is ultrasonically treated, obtains the oxidation of a concentration of 0.25-1.5mg/mL
Graphene dispersing solution；
7) step 5) reaction solution is mixed with graphene oxide dispersion, is stirred 12-24 hours under the conditions of 50-80 DEG C, dialysed
7-10 days, freeze-drying obtained medical graphene oxide antiseptic.
2. the preparation method of medical graphene oxide antiseptic according to claim 1, it is characterised in that：In step 1), institute
The pH ranges for the 2-morpholine ethane sulfonic acid buffer solution stated are between 5.5-6.5.
3. the preparation method of medical graphene oxide antiseptic according to claim 1, it is characterised in that：In step 1), institute
A concentration of the 25% of the water concentration for three sodium alkoxide of carboxyethylsilane stated.
4. the preparation method of medical graphene oxide antiseptic according to claim 1, it is characterised in that：In step 3), institute
The tetrapeptide stated is arginine-glycine-aspartic acid-lysine.
5. the preparation method of medical graphene oxide antiseptic according to claim 1, it is characterised in that：That is mould for the card
Element is kanamycin sulfate.
6. the preparation method of medical graphene oxide antiseptic according to claim 1, it is characterised in that：In step 6), institute
The supersound process stated is that ultrasound 300-1000W is handled 5-30 minutes.
7. a kind of obtained doctor of preparation method by the medical graphene oxide antiseptic described in claim 1-5 any one
With graphene oxide antiseptic.
8. medical graphene oxide antiseptic according to claim 7, which is characterized in that structural formula is as follows：
9. application of the medical graphene oxide antiseptic in antibacterial described in claim 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810103737.4A CN108310392B (en) | 2018-02-01 | 2018-02-01 | Preparation method of medical graphene oxide antibacterial agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810103737.4A CN108310392B (en) | 2018-02-01 | 2018-02-01 | Preparation method of medical graphene oxide antibacterial agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108310392A true CN108310392A (en) | 2018-07-24 |
| CN108310392B CN108310392B (en) | 2020-06-16 |
Family
ID=62890503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810103737.4A Expired - Fee Related CN108310392B (en) | 2018-02-01 | 2018-02-01 | Preparation method of medical graphene oxide antibacterial agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108310392B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109964955A (en) * | 2019-03-29 | 2019-07-05 | 四川大学 | A kind of antibacterial modified graphene oxide and preparation method thereof |
| CN110101870A (en) * | 2019-05-23 | 2019-08-09 | 江南大学 | Long-chain alkyl lycine-graphene quantum dot complex antimicrobials and preparation method thereof |
| CN110973156A (en) * | 2019-11-28 | 2020-04-10 | 自然资源部第三海洋研究所 | Graphene oxide/rosmarinic acid composite material and preparation method thereof |
| CN112023058A (en) * | 2019-06-04 | 2020-12-04 | 成都中医药大学 | Graphene oxide-based beta-lactam antibiotic and preparation method thereof |
| WO2021252382A1 (en) * | 2020-06-08 | 2021-12-16 | The Texas A&M University System | Therapeutic carbon nanomaterial h2s oxidants for biological polysulfide synthesis |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191467A (en) * | 2013-04-07 | 2013-07-10 | 西南交通大学 | Preparation method for antibacterial coat for fixing various cell growth factors on medical metal |
| US20130266628A1 (en) * | 2012-04-10 | 2013-10-10 | Indian Institute Of Technology Madras | Graphene-based antimicrobial composites |
| CN104472538A (en) * | 2014-11-24 | 2015-04-01 | 暨南大学 | Functional graphene oxide loaded nano-silver antibacterial material as well as preparation method and application thereof |
| CN104922675A (en) * | 2015-05-25 | 2015-09-23 | 东华大学 | Preparation method of graphene oxide composite material mediated by carboxymethyl chitosan and modified by hyaluronic acid |
| CN105793190A (en) * | 2013-03-15 | 2016-07-20 | 南洋理工大学 | Hybrid nanomaterial of graphene oxide nanomaterial and cationic quaternized chitosan |
| KR20160110643A (en) * | 2015-03-10 | 2016-09-22 | 한국표준과학연구원 | Sensor for detecting botulinum neurotoxin and a detection method using the FRET |
-
2018
- 2018-02-01 CN CN201810103737.4A patent/CN108310392B/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130266628A1 (en) * | 2012-04-10 | 2013-10-10 | Indian Institute Of Technology Madras | Graphene-based antimicrobial composites |
| CN105793190A (en) * | 2013-03-15 | 2016-07-20 | 南洋理工大学 | Hybrid nanomaterial of graphene oxide nanomaterial and cationic quaternized chitosan |
| CN103191467A (en) * | 2013-04-07 | 2013-07-10 | 西南交通大学 | Preparation method for antibacterial coat for fixing various cell growth factors on medical metal |
| CN104472538A (en) * | 2014-11-24 | 2015-04-01 | 暨南大学 | Functional graphene oxide loaded nano-silver antibacterial material as well as preparation method and application thereof |
| KR20160110643A (en) * | 2015-03-10 | 2016-09-22 | 한국표준과학연구원 | Sensor for detecting botulinum neurotoxin and a detection method using the FRET |
| CN104922675A (en) * | 2015-05-25 | 2015-09-23 | 东华大学 | Preparation method of graphene oxide composite material mediated by carboxymethyl chitosan and modified by hyaluronic acid |
Non-Patent Citations (4)
| Title |
|---|
| HAIBO WANG，ET AL: ""Graphene Oxide–Peptide Conjugate as an Intracellular Protease Sensor for Caspase-3 Activation Imaging in Live Cells"", 《ANGEW. CHEM. INT. ED. 》 * |
| LIN SHI，ET AL: ""Modifying graphene oxide with short peptide via click chemistry for biomedical applications"", 《APPLIED MATERIALS TODAY》 * |
| RAJASHEKHAR KANCHANAPALLY，ET AL: ""Antimicrobial peptide-conjugated graphene oxide membrane for efficient removal and effective killing of multiple drug resistant bacteria"", 《RSC ADVANCES》 * |
| 汪蕾等: ""氧化石墨烯负载螺旋抗菌肽制备杂化功能材料"", 《中国化学会第十五届胶体与界面化学会议论文集（第二分会）》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109964955A (en) * | 2019-03-29 | 2019-07-05 | 四川大学 | A kind of antibacterial modified graphene oxide and preparation method thereof |
| CN110101870A (en) * | 2019-05-23 | 2019-08-09 | 江南大学 | Long-chain alkyl lycine-graphene quantum dot complex antimicrobials and preparation method thereof |
| CN110101870B (en) * | 2019-05-23 | 2021-01-29 | 江南大学 | Long-chain alkyl betaine-graphene quantum dot composite antibacterial agent and preparation method thereof |
| CN112023058A (en) * | 2019-06-04 | 2020-12-04 | 成都中医药大学 | Graphene oxide-based beta-lactam antibiotic and preparation method thereof |
| CN112023058B (en) * | 2019-06-04 | 2022-10-18 | 成都中医药大学 | Graphene oxide-based beta-lactam antibiotic and preparation method thereof |
| CN110973156A (en) * | 2019-11-28 | 2020-04-10 | 自然资源部第三海洋研究所 | Graphene oxide/rosmarinic acid composite material and preparation method thereof |
| WO2021252382A1 (en) * | 2020-06-08 | 2021-12-16 | The Texas A&M University System | Therapeutic carbon nanomaterial h2s oxidants for biological polysulfide synthesis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108310392B (en) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108310392A (en) | A kind of preparation method of medical graphene oxide antiseptic | |
| CN107971481B (en) | Gold nanocluster with antibacterial activity and preparation method and application thereof | |
| CN108992464B (en) | Polypeptide-silver nanocluster compound and preparation method and application thereof | |
| Zholobak et al. | Interaction of nanoceria with microorganisms | |
| He et al. | Preparation and antibacterial properties of O-carboxymethyl chitosan/lincomycin hydrogels | |
| CN102311492A (en) | Non-natural fully D-type snake venom cathelicidin antibacterial peptide and derivative, preparation method as well as application thereof | |
| CN107997984A (en) | A kind of antibacterial peptide-chitosan complexes, its preparation method and its application | |
| CN108339977A (en) | A kind of preparation method and application of chitosan oligosaccharide nano silver composite antibacterial agent | |
| CN101589854A (en) | A kind of air filter type bacterial cellulose mask and production method thereof | |
| CN111602672B (en) | Antibacterial nano material and preparation method and application thereof | |
| CN111280182A (en) | Active peptide composition and application thereof | |
| CN107252475B (en) | The application of natural host defense peptide Alligatorin4 | |
| CN102294019A (en) | Application of cathelicidin-BF | |
| Xu et al. | Preparation and characterization of a novel polysialic acid/gelatin composite hydrogels cross-linked by tannic acid to improve wound healing after cesarean section dressing | |
| CN110506884A (en) | A kind of double lysine antibacterial agents and preparation method and application | |
| CN112089730A (en) | Antibacterial iron sulfide aqueous solution, preparation method and application thereof | |
| Lee et al. | Apoptotic cell death induced by Acinetobacter baumannii in epithelial cells through caspase‐3 activation Note | |
| Hu et al. | Preparation and characterization of nisin‐loaded chitosan nanoparticles functionalized with DNase I for the removal of Listeria monocytogenes biofilms | |
| CN111632188A (en) | Seaweed polysaccharide composite biological matrix dressing and preparation method thereof | |
| CN108420803A (en) | Nano enzyme adhesive bandage, preparation method and application method | |
| Pongsamart et al. | Novel water soluble antibacterial dressing of durian polysaccharide gel | |
| CN107137707A (en) | Chitosan-modified magnetic heterojunction structure and its application at antibacterial aspect | |
| CN111744050A (en) | Preparation method and wound healing method of graphene oxide-daptomycin/epidermal growth factor composite dressing | |
| Lagat | Biological and Chemical Extraction of Chitin and Chitosan from the Black Soldier Fly (Hermetia illucens) Exoskeleton and Antimicrobial Activity Against Selected Human Pathogenic Microbes | |
| CN108553409A (en) | A kind of Epigallo-catechin gallate (EGCG) nano wire preparation and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200616 Termination date: 20210201 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |